SUPERNUS executive receives new option and RSU awards

SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026.

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026. He received an option to buy 13,500 shares of common stock and 3,000 restricted stock units, both granted at $0.00 per share as compensation.

The option and RSUs vest in four equal annual installments beginning on February 18, 2027. Following these awards, Bhatt directly holds 14,900 shares of common stock, which includes 392 shares acquired through the company’s employee stock purchase plan, along with the new option and RSU positions.

Insider Trade Summary

Grant/Award: 16,500 shares

Grant/Award 3 txns

Insider Bhatt Padmanabh P.

Role Sr. VP of IP, CSO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	13,500	$0.00	$0.00
Grant/Award	Restricted Stock Unit	3,000	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 13,500 contracts (Direct); Restricted Stock Unit — 3,000 contracts (Direct); Common Stock — 14,900 shares (Direct)

Footnotes (4)

1. F1. Includes an aggregate of 392 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
2. F2. The option vests in four equal annual installments beginning on February 18, 2027.
3. F3. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
4. F4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN executive Padmanabh Bhatt report on February 18, 2026?

On February 18, 2026, Padmanabh P. Bhatt reported receiving an option for 13,500 shares and 3,000 restricted stock units of Supernus common stock. Both awards were granted at $0.00 per share as part of his equity-based compensation package.

How do the new stock option awards for SUPN’s Padmanabh Bhatt vest?

Bhatt’s 13,500-share stock option vests in four equal annual installments beginning on February 18, 2027. This structure spreads the vesting over four years, encouraging long-term alignment with Supernus Pharmaceuticals’ performance and providing a staggered schedule for potential future share exercises.

What are the terms of the 3,000 restricted stock units granted to SUPN executive Padmanabh Bhatt?

Each of Bhatt’s 3,000 restricted stock units equals one share of Supernus common stock upon vesting. These RSUs are settled in stock and vest in four equal annual installments starting February 18, 2027, creating a multi-year incentive tied directly to the company’s equity.

How many shares of Supernus common stock does Padmanabh Bhatt hold after these transactions?

After the reported awards, Bhatt directly holds 14,900 shares of Supernus common stock. This figure includes 392 shares acquired through the company’s Employee Stock Purchase Plan, in addition to his existing holdings and the newly granted option and RSU interests.

Are the February 18, 2026 SUPN equity awards to Padmanabh Bhatt open-market purchases?

No, the February 18, 2026 transactions are equity grants, not open-market purchases. The Form 4 identifies them as awards with a transaction code A, reflecting grant or other acquisition, and specifies a grant price of $0.00 per share for both options and RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatt Padmanabh P.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of IP, CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								14,900(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$50.2	02/18/2026		A		13,500		(2)	02/18/2036	Common Stock	13,500	$0	13,500	D
Restricted Stock Unit	(3)	02/18/2026		A		3,000		(4)	(4)	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. Includes an aggregate of 392 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. The option vests in four equal annual installments beginning on February 18, 2027.

3. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.